(S)-2-(1,3-Dioxoisoindolin-2-yl)-4-methylpentanoic acid

Catalog No. :
ACYHBT107
CAS No. :
2419-38-7
Molecular Formula :
C14H15NO4
Molecular Weight :
261.28

IUPAC Name:(S)-2-(1,3-dioxoisoindolin-2-yl)-4-methylpentanoic acid

(S)-2-(1,3-Dioxoisoindolin-2-yl)-4-methylpentanoic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
25g98%$106.00Login to see priceIn stockInquiry
100g98%$358.00Login to see priceIn stockInquiry
500g98%$1255.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(S)-2-(1,3-Dioxoisoindolin-2-yl)-4-methylpentanoic acid
IUPAC Name(S)-2-(1,3-dioxoisoindolin-2-yl)-4-methylpentanoic acid
MDL No.MFCD00065026
Molecular FormulaC14H15NO4
Molecular Weight261.28
SMILESCC(C)C[C@@H](C(O)=O)N1C(C2=CC=CC=C2C1=O)=O
InChI KeyRMOSZIHTPMEZAP-NSHDSACASA-N
SynonymAM20030430 | N-Alpha-phthaloyl-L-leucine | PHT-LEU-OH | 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-4-methylpentanoic acid # | (2S)-2-(1,3-dioxoisoindolin-2-yl)-4-methyl-pentanoic acid | AKOS023033847 | D78914 | CS-0273772 | (2S)-2-(1,3-dioxo-2,3-dihydro-1
CAS No.2419-38-7
PubChem CID688554

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACYHBT107 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCWFM015 route compound structure diagram
    ACCWFM015760-84-9 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACYHBT107 route product structure diagram
    ACYHBT1072419-38-7 In Stock
Inquiry

2. ACYHBT107 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCWFM015 route compound structure diagram
    ACCWFM015760-84-9 In Stock
  2. Then
  3. ACYHBT107 route product structure diagram
    ACYHBT1072419-38-7 In Stock
Inquiry

Comments (0)